Despite conflicting data, a recent meta-analysis suggests that KRAS mutations may represent a negative prognostic factor for survival and response outcomes to several different treatments (including ICI) in patients with advanced/metastatic NSCLC [54]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.